Clinical narratives that describe complex medical events are often accompanied by meta-information such as a patient’s demographics, diagnoses and medications. This structured information implicitly relates to the logical and semantic structure of the entire narrative, and thus affects vocabulary choices for the narrative composition. To leverage this meta-information, we propose a supervised topic compositional neural language model, called MeTRNN, that integrates the strength of supervised topic modeling in capturing global semantics with the capacity of contextual recurrent neural networks (RNN) in modeling local word dependencies. MeTRNN generates interpretable topics from global meta-information and uses them to facilitate contextual RNNs in modeling local dependencies of text. For efficient training of MeTRNN, we develop an autoencoding variational Bayes inference method. We evaluate MeTRNN on the word prediction tasks using public text datasets. MeTRNN consistently outperforms all baselines across all datasets in perplexity ranging from 5% to 40%. Our case studies on real world electronic health records (EHR) data show that MeTRNN can learn and benefit from meaningful topics.

Adverse drug reactions (ADRs) caused by drug-drug interactions (DDI) are a major cause of morbidity and mortality worldwide. There is a growing need for computing-supported methods that facilitate the automated signaling of DDI related ADRs (DIARs) that otherwise would remain undiscovered in millions of ADR reports. In this demonstration, we showcase our MeDIAR technology - an end-to-end DIAR signal generation, exploration and validation solution for pharmaceutical regulatory agencies to detect true DIAR signals from a drug surveillance database. MeDIAR's innovations include an efficient rule-driven learning algorithm for deriving DIAR signals from ADR reports, an innovative scoring methodology based on the proposed contextual association cluster model to rank the generated signals by their importance. Further, these ranked signals are augmented with meta information such as their significance level and their severity, along with links to their supporting ADR reports. Lastly, MeDIAR features an interactive visual analytics interface to support drug safety evaluators in reviewing and discovering unknown severe DIARs.

There is a growing need for computing-supported methods that facilitate the automated signaling of Adverse Drug Reactions (ADRs) otherwise left undiscovered from the exploding amount of ADR reports filed by patients, medical professionals and drug manufacturers. In this research, we design a Multi-Drug Adverse Reaction Analytics Strategy, called MARAS, to signal severe unknown ADRs triggered by the usage of a combination of drugs, also known as Multi-Drug Adverse Reactions (MDAR). First, MARAS features an efficient signal generation algorithm based on association rule learning that extracts non-spurious MDAR associations. Second, MARAS incorporates contextual information to detect drug combinations that are strongly associated with a set of ADRs. It groups related associations into Contextual Association Clusters (CACs) that then avail contextual information to evaluate the significance of the discovered MDAR Associations. Lastly, we use this contextual significance to rank discoveries by their notion of interestingness to signal the most compelling MDARs. To demonstrate the utility of MARAS, it is compared with state-of-the-art techniques and evaluated via case studies on datasets collected by U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).